Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Medical Device

Nanjing Novlead Bio Files Hong Kong IPO – Nitric Oxide Therapy Specialist Targets Critical Care Market

Fineline Cube Mar 3, 2026
Company Deals

Boehringer Ingelheim Licenses Sitryx Autoimmune Program – $500M+ Deal for Oral Disease‑Modifying Therapy

Fineline Cube Mar 3, 2026
Company Deals

ArkBio Partners with Qilu Pharma on Azstarys China Commercialization – ADHD Therapy Market Entry

Fineline Cube Mar 3, 2026
Company Deals

QL Biopharma Raises 500M+ RMB Series C – OrbiMed Leads Round for Monthly GLP‑1 Zovigrutide

Fineline Cube Mar 2, 2026
Company Deals

Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars

Fineline Cube Feb 27, 2026
Policy / Regulatory

NMPA CDE Launches “Caring Program – Extension” Pilot – Accelerates Rare Disease Drug Development Pathway

Fineline Cube Mar 2, 2026
Company Drug

Huadong Medicine’s DR30206 Wins NMPA Approval – Triple‑Target Fusion Protein for NSCLC Enters Phase II

Fineline Cube Mar 3, 2026
Company Drug

Hua Medicine’s Dorzagliatin Wins Hong Kong Approval – First‑in‑Class GKA Enters Market for Type 2 Diabetes

Fineline Cube Mar 3, 2026
Company Deals

Bayer’s Leap Forward: Implementing Salesforce on Alibaba Cloud for Customer Engagement

Fineline Cube Nov 8, 2024

Bayer (ETR: BAYN) has announced that its China Prescription Medicines business has fully adopted the...

Company Drug Policy / Regulatory

CDE Releases Technical Guidelines for Pilot Registration and Phased Manufacturing of ADCs

Fineline Cube Nov 8, 2024

The Center for Drug Evaluation (CDE) has issued the “Technical Requirements for Pilot Registration and...

Company Deals

Shanghai Pharmaceuticals’ MediTrust Health Partners with Eisai for Comprehensive Patient Services

Fineline Cube Nov 8, 2024

Shanghai Pharmaceuticals Holding Co., Ltd’s (HKG: 2607, SHA: 601607) subsidiary, MediTrust Health, which specializes in...

Company Deals

Boehringer Ingelheim Partners with Wuhan Union Hospital to Enhance Clinical Research and Development

Fineline Cube Nov 8, 2024

Boehringer Ingelheim, a leading German pharmaceutical company, has entered into a strategic partnership with Wuhan...

Policy / Regulatory

NHSA and MCA Boost Medical Assistance with Enhanced Information Sharing Measures

Fineline Cube Nov 8, 2024

The National Healthcare Security Administration (NHSA) and the Ministry of Civil Affairs (MCA) have jointly...

Company Deals

Hainan Haiyao Enters JV with Haikou and Xenios AG to Advance ECMO Technology

Fineline Cube Nov 8, 2024

Hainan Haiyao Co., Ltd (SHE: 000566), a prominent Chinese company, has announced the signing of...

Company Drug

Belief BioMed’s BBM-D101 Receives FDA Orphan Drug and Pediatric Rare Disease Designations for DMD

Fineline Cube Nov 7, 2024

Belief BioMed has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan...

Company Deals

Nanjing Leads Biolabs and Aditum Bio Launch Oblenio Bio with Focus on CD19 Tri-Specific Antibody

Fineline Cube Nov 7, 2024

China-based Nanjing Leads Biolabs Co., Ltd and venture capital firm Aditum Bio have announced the...

Company Deals

Sanofi and Cathay Capital Forge Partnership to Boost Sino-French Pharmaceutical Cooperation

Fineline Cube Nov 7, 2024

French pharmaceutical giant Sanofi (NASDAQ: SNY) has signed a partnership deal with Cathay Capital, a...

Company Deals

Eisai and GE Healthcare Sign MoU at CIIE to Collaborate on Alzheimer’s Disease Solutions

Fineline Cube Nov 7, 2024

At the 7th China International Import Expo (CIIE), Japan-based Eisai Co., Ltd (TYO: 4523) entered...

Company Deals

Lohmann & Rauscher Partners with Allmed Medical Products at CIIE for Medical Dressings

Fineline Cube Nov 7, 2024

Lohmann & Rauscher, a medical group with headquarters in Germany and Austria, has entered into...

Company

I-Mab Appoints Sean (Xi-Yong) Fu as Permanent CEO, Effective November 1, 2024

Fineline Cube Nov 7, 2024

US-based biopharmaceutical company I-Mab (NASDAQ: IMAB) has announced the appointment of Sean (Xi-Yong) Fu, PhD,...

Company

Novo Nordisk Reports Q3 2024 Financials with 24% YOY Revenue Growth

Fineline Cube Nov 7, 2024

Denmark-based pharmaceutical company Novo Nordisk A/S (NYSE: NVO) has released its financial results for the...

Company Deals

Shanghai Pharmaceutical Co., Ltd Secures Multiple Partnerships at CIIE

Fineline Cube Nov 7, 2024

At the 7th China International Import Expo (CIIE), China-based Shanghai Pharmaceutical Co., Ltd (SPH, SHA:...

Company Medical Device

Siemens Healthineers AG Reports Fiscal 2024 Results with Targeted Revenue Growth

Fineline Cube Nov 7, 2024

Germany-based medical device giant Siemens Healthineers AG (ETR: SHL) has released its financial results for...

Company Drug

HutchMed to Present Updated Data from Solvleplenib ESLIM-01 Phase III Trial at ASH and ESMO Congress 2024

Fineline Cube Nov 7, 2024

China-based HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced plans to present new and...

Company Deals

Bayer HealthCare Partners with China Population Welfare Foundation at CIIE for Public Health Initiatives

Fineline Cube Nov 7, 2024

German pharmaceutical giant Bayer HealthCare (FRA: BAYN) has entered into a partnership agreement with the...

Company Deals

Medtronic Partners with China Resources Guangdong Pharmaceutical at CIIE for Medical Equipment Development

Fineline Cube Nov 7, 2024

US-Irish firm Medtronic (NYSE: MDT) has entered into a partnership with China-based China Resources Guangdong...

Company Drug

Pfizer’s Talzenna (talazoparib) Approved by China’s NMPA for mCRPC Treatment

Fineline Cube Nov 7, 2024

The National Medical Products Administration (NMPA) website has indicated that Pfizer’s (NYSE: PFE) marketing filing...

Company Drug

Shouyao Holdings Adjusts Development Strategy for SY-1530, Halts Monotherapy Clinical Trials

Fineline Cube Nov 7, 2024

Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) has announced a strategic adjustment regarding its...

Posts pagination

1 … 234 235 236 … 629

Recent updates

  • MicroPort Endovascular’s Hector Wins FDA Breakthrough Designation – Multi‑Branch Stent Graft Targets Complex Aortic Arch Lesions
  • Huadong Medicine’s DR30206 Wins NMPA Approval – Triple‑Target Fusion Protein for NSCLC Enters Phase II
  • Hua Medicine’s Dorzagliatin Wins Hong Kong Approval – First‑in‑Class GKA Enters Market for Type 2 Diabetes
  • Lepu Medical’s siRNA MWX401 Wins NMPA Approval – RNAi Therapy Targets Primary Hypertension
  • Xellsmart’s iPSC Neural Therapy Cleared by NMPA and FDA – First “Off‑the‑Shelf” Cell Therapy for MSA‑P Enters Clinic
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Medical Device

MicroPort Endovascular’s Hector Wins FDA Breakthrough Designation – Multi‑Branch Stent Graft Targets Complex Aortic Arch Lesions

Company Drug

Huadong Medicine’s DR30206 Wins NMPA Approval – Triple‑Target Fusion Protein for NSCLC Enters Phase II

Company Drug

Hua Medicine’s Dorzagliatin Wins Hong Kong Approval – First‑in‑Class GKA Enters Market for Type 2 Diabetes

Company Drug

Lepu Medical’s siRNA MWX401 Wins NMPA Approval – RNAi Therapy Targets Primary Hypertension

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.